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postfusion conformation. We hypothesize that an interaction between the C-terminal 23 arm and the central coiled-coil of the herpes simplex virus 1 (HSV-1) gB ectodomain is 24 critical for fusion. We previously reported that three mutations in the C-terminal arm 25 (I671A/H681A/F683A, called gB3A) greatly reduced cell-cell fusion and that virus 26 carrying these mutations had a small plaque phenotype and delayed entry into cells. By 27 serially passaging gB3A virus, we selected three revertant viruses with larger plaques. 28
These revertant viruses acquired mutations in gB that restore the fusion function of 29 gB3A, including gB-A683V, gB-S383F/G645R/V705I/A855V, and gB-T509M/N709H. 30 V705I and N709H are novel mutations that map to the portion of domain V that enters 31 domain I in the postfusion structure. S383F, G645R, and T509M are novel mutations 32 that map to an intersection of three domains in a prefusion model of gB. We introduced 33 these second-site mutations individually and in combination into wild-type gB and gB3A 34 to examine the impact of the mutations on fusion and expression. V705I and A855V (a 35 known hyperfusogenic mutation) restored the fusion function of gB3A, whereas S383F 36 and G645R dampened fusion and T509M and N709H worked in concert to restore 37 gB3A fusion. The results identify two regions in the gB ectodomain that modulate the 38 fusion activity of gB, potentially by impacting intramolecular interactions and stability of 39 the prefusion and/or postfusion gB trimer. 40
INTRODUCTION 55
Herpes simplex virus (HSV) causes recurrent mucocutaneous lesions on the 56 mouth, face or genitalia and spread to the central nervous system which can lead to 57 meningitis or encephalitis (1). Infection of host cells occurs by fusion of the virion 58 envelope with a cell membrane to deliver the nucleocapsid and the viral genome into 59 the host cell. HSV entry into cells and virus-induced cell-cell fusion require the 60 coordinated action of the four viral entry glycoproteins: glycoprotein D (gD), gH, gL, and 61 gB. The binding of gD to receptor results in a conformational change in gD that is 62 proposed to signal the gHgL heterodimer to trigger the fusogenic activity of gB (2-4). 63 gB is a trimeric class III viral fusion protein that is conserved across all 64 herpesviruses (5-7). Upon triggering, gB inserts into the cellular membrane and refolds 65 from a prefusion to a postfusion conformation to bring the viral and cell membranes 66 together. The structures of the postfusion forms of gB from three herpesviruses have 67 been solved (5, 8-10). To date, attempts to capture a stable prefusion form of HSV-1 gB 68 for crystallization have been unsuccessful (11). Alternative gB conformations have been 69 modeled recently using cryoelectron tomography of gB present on membranes (12, 13) . 70
A prefusion model of gB has been developed using the crystal structure of the class III 71 fusion protein from vesicular stomatitis virus (VSV) (14-16). 72
Our previous site-directed mutagenesis study demonstrated that fusion was 73 impaired by mutations in an extended arm at the C-terminus of the ectodomain (domain 74 V) that packs against the coiled-coil core of gB (domain III) in the post-fusion 75 conformation (17). Alanine substitutions in three arm residues (I671A, H681A, and 76 F683A; termed gB3A in this paper) that were predicted to disrupt interactions between 77 the arm and coil greatly reduced fusion in a quantitative cell-cell fusion assay, indicating 78 that the gB arm is important for fusion. Fusion function in gB3A was restored by the 79 addition of a known hyperfusogenic mutation in the gB cytoplasmic tail, suggesting that 80 the gB3A mutations did not cause global misfolding of gB. Due to the similarity of this 81 gB coil-arm complex to the six-helix bundle of class I fusion proteins (18), we 82 hypothesized that the gB coil-arm interactions were important for the transition from a 83 prefusion to a postfusion gB conformation. 84
To further investigate the role of the gB arm region in virus entry, we generated 85 and characterized HSV-1 carrying the gB3A mutations. This gB3A virus had small 86 5 plaques, impaired growth, and delayed penetration into cells that was restored partially 87 at elevated temperatures (19). These results supported our hypothesis that the gB3A 88 mutations alter fusion kinetics by stabilizing a prefusion or intermediate conformation of 89 gB or destabilizing the postfusion conformation. 90
In the present study, we passaged gB3A virus and selected for large plaque variants 91 to identify mutations within gB that could restore gB3A fusion function. We selected 92 three independent revertant viruses and sequencing revealed that all three viruses 93 acquired mutations in gB. We cloned gB from the revertant viruses and introduced the 94 mutations into wild-type (WT) gB and gB3A to analyze the effect of these mutations on 95 cell surface expression and cell-cell fusion activity when coexpressed with WT gD, gH, 96 and gL. The second-site revertant mutations identified two regions that modulate the 97 fusion activity of gB3A: the C-terminus of the gB ectodomain and the intersection of 98 three domains in a model of prefusion gB. 99
100

RESULTS 101
Selection of gB3A revertant viruses. Since gB3A virus exhibited delayed entry 102 and a small plaque phenotype (19), we used serial passage to select for second-site 103 mutations that would rescue the gB3A plaque morphology. We hypothesized that the 104 location of these second-site mutations would reveal gB sites of functional importance, 105 potentially including residues that affect the stability of gB and/or interact with the 106 domain V arm region in a prefusion or intermediate gB conformation. Since our previous 107 study showed that truncating the cytoplasmic tail of gB3A restored its fusion activity 108 6 (17), we had reason to expect that second site mutations in gB would be able rescue 109 the gB3A fusion defect. 110
Three independently purified stocks of DNA from a BAC carrying gB3A (pQF297) 111 (19) were transfected individually into Vero cells expressing Cre recombinase to excise 112 the BAC backbone. Virus harvested from these cells was amplified in Vero cells to 113 generate three independent gB3A virus stocks. To select for revertant viruses 114 possessing a growth advantage linked to a restoration of fusion function, these gB3A 115 stocks were passaged serially in Vero cells. Virus harvested from each passage was 116 titered to facilitate calculation of a multiplicity of infection (MOI) of 0.01 for the next 117 passage. After serial passage, larger plaques were observed during titration and the 118 infections spread faster in culture than the parental gB3A virus. For example, prior to 119 passage 15, the gB3A virus stock designated 58621 required 7-15 days between 120 passages to reach full cytopathic effect (CPE). By passage 20, CPE developed at the 121 same rate for the 58621 infection and WT infections. By passage 24, the majority of 122 plaques from the 58621 infection were large. 123
Large plaque revertant viruses carry mutations in gB. A single large plaque 124
revertant was selected from each of the three independently passaged gB3A stocks and 125 the revertant virus was plaque purified. Viral DNA from the revertant viruses was used 126 to clone and sequence the gB gene to allow us to examine the effect of gB mutations on 127 fusion function in the absence of other viral genes that may have acquired mutations 128 during the serial passaging. Sequencing results revealed that each revertant virus 129 acquired distinct mutations within gB, including a single mutation A683V (isolated at 7 passage 6), a quadruple mutation S383F/G645R/V705I/A855V (isolated at passage 25), 131 and a double mutation T509M/N709H (isolated at passage 30). 132
Fusion restoration in the gB3A-A683V revertant. The gB3A-A683V revertant 133 virus demonstrated a larger plaque size than the parental gB3A virus, with a plaque 134 morphology that resembled WT HSV (Fig. 1) . The A683V mutation directly changes one 135 of the original residues mutated in gB3A. Residue 683 is an alanine in gB3A and a 136 phenylalanine in WT gB. 137
To assess the impact of the A683V mutation on fusion, the gB gene from this 138 revertant virus was cloned into an expression vector (gB3A-A683V) with an N-terminal 139 FLAG tag added to facilitate comparison of expression levels. This valine substitution at 140 683 also was added to a FLAG-tagged version of WT gB (gB-F683V). A virus-free cell-141 cell fusion assay was used to examine mutant gB fusion function. In this assay, one set 142 of cells expressing T7 polymerase, gD, gH, gL, and version of gB is cocultured with a 143 second set of cells expressing with an HSV receptor and luciferase under the control of 144 the T7 promoter. Luciferase expression is used to quantify cell-cell fusion. As we 145 previously reported, gB3A mediated nearly undetectable fusion ( Fig. 2 ) (17). gB3A-146 A683V partially restored fusion, compared to gB3A, consistent with the restoration of 147 plaque size exhibited by the revertant virus. gB-F683V showed reduced fusion 148 compared to WT gB, indicating that, although a valine is functional in this position, a 149 phenylalanine at this position promotes greater fusion. Interestingly, FLAG-tagged gB3A 150 showed impaired cell surface expression compared to FLAG-tagged WT gB (Fig. 2) . 151
This effect on gB3A expression was unexpected because the FLAG-tagged WT gB and 152 untagged WT gB have similar levels of surface expression (data not shown). The 153 8 addition of the A683V mutation to FLAG-tagged gB3A restored expression, which may 154 partially account for restoration of fusion function. 155
Fusion restoration in the gB3A-S383F/G645R/V705I/A855V revertant. The 156 gB3A-S383F/G645R/V705I/A855V revertant virus demonstrated a larger plaque size 157 than the parental gB3A virus, with a plaque morphology that resembles a syncytial virus 158 ( Fig. 1 ). This morphology agrees with previous work that identified gB-A855V as a 159 syncytial mutation (20, 21). 160
The gB gene from this quadruple mutant was cloned into the same expression 161 vector as above (gB3A-S383F/G645R/V705I/A855V) to assay the effect of these 162 mutations on cell-cell fusion and cell surface expression. The revertant gB carrying the 163 four second-site mutations exhibited nearly WT levels of both cell surface expression 164 and fusion (Fig. 3A ). This restoration of fusion is consistent with restored plaque size of 165 the revertant virus. As with the A683V mutant, the effect of the second-site mutations on 166 the surface expression of FLAG-gB3A may contribute to enhanced fusion. 167
Sequencing the gB gene from earlier passages of this revertant virus that were 168 not plaque purified showed that the G645R and A855V mutations (present at passage 169 8) appeared before the S383F mutation (present at passage 10) and that the V705I 170 mutation appeared last (present in the final passage 25). 171
To examine how the four amino acid changes in the revertant virus may 172
contribute to the restoration of plaque size, the mutations were introduced into gB singly 173 or in combination. The four mutations were introduced individually into FLAG-tagged 174 9 construct were mutated individually back to their corresponding WT residues. Four 176 additional double mutations were also generated in the gB3A background. 177
Introduction of any one of the second-site mutations into WT gB did not affect the 178 cell surface expression levels (Fig. 3A ). As expected, A855V enhanced cell-cell fusion 179 when added to WT gB (Fig. 3A, column 8 ). The A855V mutation was shown previously 180 to enhance cell-cell fusion (22, 23) . Individual introduction of the other three second-site 181 mutations into WT gB enhanced fusion only modestly. 182
The addition of S383F or G645R to gB3A did not alter cell surface expression or 183 fusion substantially. The addition of A855V to gB3A enhanced fusion to greater than WT 184 levels ( Fig. 3A, column 12 ), similar to the results observed in the WT gB background. virus, with a plaque morphology resembling WT HSV ( Fig. 1 ). Both of these mutations 208 are in the gB ectodomain and neither were previously reported to be hyperfusogenic. 209
Interestingly, in the postfusion structure of gB, T509 is a contact residue for F683, 210 located in the central trimeric coiled-coil. To examine the impact of these mutations on 211 gB expression and fusion, the gB gene from this virus was cloned into the same 212 expression vector as above (gB3A-T509M/N709H). The addition of these two mutations 213 to gB3A enhanced fusion ( Fig. 4) , consistent with the larger plaque phenotype of this 214 virus. As with the previous two revertant gB constructs, the expression of the revertant 215 gB was enhanced compared to FLAG-gB3A, which may contribute to improved fusion 216 function. When the mutations were added individually to WT gB, neither mutation 217 enhanced fusion ( Fig. 4) , indicating that these mutations are not hyperfusogenic like 218 A855V. In fact, both of the mutations somewhat decreased fusion mediated by WT gB. 219
When the mutations were added individually to gB3A, no fusion was detected ( Fig. 4) , 220
indicating that neither mutation alone can rescue the fusion defect imparted by gB3A. 221
11
The mutations act in combination to restore fusion mediated by gB3A and are of 222 particular interest because they have not been previously described and they map to 223 two sites in the prefusion and postfusion gB structures that correspond with the gB3A-224
The gB3A mutations (I671A/H681A/F683A) were designed based on the 228 postfusion structure of gB (5) to reduce interactions between the domain V arm and the 229 central coiled-coil (17). We previously showed that these mutations inhibited cell-cell 230 fusion and virus carrying these mutations exhibited a growth defect and formed 200-fold 231 smaller plaques than WT virus (19). To investigate how these gB3A mutations inhibit 232 fusion, we serially passaged BAC-derived gB3A virus to select for mutations that 233 overcome the fusion defect and restore a larger plaque size. Three revertant viruses 234 were isolated and all three viruses carried mutations in gB3A. 235
To examine whether the newly acquired mutations in gB3A could account for the 236 restored plaque size, we cloned the gB genes from these viruses into expression 237 vectors. The second-site mutations enhanced gB3A cell-cell fusion, suggesting that 238 these mutations were responsible for the larger plaque size. Thus, natural selection 239 identified several second-site gB mutations that restore gB3A function. Although 240 additional mutations outside of gB also may have contributed to the restored plaque 241 size and/or growth of the revertant viruses, cloning the revertant gB genes allowed us to 242 analyze the effect of the gB mutations in isolation when coexpressed with WT gD, gH, 243 and gL. 244
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The gB3A-A683V virus acquired a change in residue 683, one of the residues 245 originally mutated to alanine in gB3A. Selection of this revertant mutation underscores 246 the importance of residue 683 to gB fusion function and demonstrates that, although in 247 WT residue 683 is a phenylalanine, a valine at this position is sufficient to promote 248 fusion better than alanine, an amino acid with a smaller side-chain ( Fig. 2A) . 249
This A683V mutation was selected independently twice upon serial passage of 250 gB3A virus (data not shown). Interestingly, among the three original mutation sites, 251
A683 was the only one changed. In postfusion WT gB, I671, H681, and F683 pack 252 against the central coiled-coil of gB (Fig. 3B ). The selection pressure for a substitution 253 at gB3A A683 rather than A681 can be explained by the structure, but the reason an 254 A683V mutation was selected over a revertant substitution in I671 is unclear. I671 and 255 F683 contact the coil more extensively than H681, with I671 and F683 contacting six 256 and five coil residues, respectively, whereas H681 contacts only three coil residues (5). 257
The side-chain atoms of I671 and F683 make 14 and 13 contacts with the coil, 258 respectively, whereas the side-chain atoms of H681 make only seven contacts. The 259 specific importance of I671 and F683 was apparent when we previously showed that 260 individually mutating F683 or I671 alanine impairs fusion more than mutating H681 (17). 261
The gB3A-S383F/G645R/V705I/A855V virus retained the original three alanine 262 mutations and acquired four additional mutations, including A855V, a known 263 hyperfusogenic mutation located in the cytoplasmic tail of gB (22). By analyzing 264 individual mutations, we confirmed that A855V alone enhances both gB3A and WT gB 265 fusion (Fig. 3A ). A855V and G645R mutations were the first mutations acquired in the 266 revertant virus, present by passage 8. The larger plaque phenotype was apparent at 267 this early passage, consistent with A855V being primarily responsible for the large 268 plaque phenotype. The structure of the gB cytoplasmic tail was solved recently (24) and 269 it forms a trimer that is proposed to stabilize prefusion gB, functioning as a clamp. 270
Residue 855 lies within a long helix that angles upwards toward the membrane. (14), is based on the prefusion structure of the VSV fusion protein (15). S383 and G645 283 sit at the intersection of domains II, III, and IV, suggesting the possibility that mutations 284 in these residues impact interdomain interactions that stabilize prefusion gB. 285 G645 lies in the middle of a stretch of three glycines. Recently, a mutation very 286 similar to G645R was selected by serial passage of a gL-null pseudorabies virus (PRV) 287 strain (27). gL-null PRV can spread cell-to-cell and passage of this virus selected for 288 several second site mutations, including PRV gB G672R. This PRV gB mutation lies in 289 a residue that corresponds to the HSV-1 gB glycine immediately adjacent to G645. PRV 290 gB G672R was shown to be a modestly hyperfusogenic mutation when added to WT 291 PRV gB. 292
In the postfusion gB structure, S383 maps in the same plane as residues H681 293 and F683 (Fig. 3B) , presenting the possibility that replacing this small polar serine with a 294 large hydrophobic phenylalanine may impact local interactions and alter how the arm 295 packs against the coiled-coil in gB3A. 296
The V705I mutation enhanced surface expression levels, restoring the gB3A 297 expression defect (Fig. 3A ). Greater surface expression may account for some of the 298 restoration of fusion function observed when V705I was added to gB3A. V705I also 299 appears to boost to gB3A fusion function directly, since the addition of V705I/A855V to 300 gB3A resulted in greater levels of fusion than the addition of A855V alone, despite 301 similar levels of surface expression for both constructs (Fig. 3A, columns 12 and 20) . 302 V705I does not impact WT gB function, indicating that the addition of this larger 303 hydrophobic side chain enhances gB3A fusion in a specific manner. Interestingly, the 304 revertant virus acquired the V705I mutation after the other three mutations. The addition 305 of V705I boosts cell-cell fusion activity compared to gB3A-S383F/G645R/A855V ( Fig.  306 3A, columns 4 and 15), bringing it to the WT gB levels, potentially the optimal level for 307 virus replication. V705 lies in domain V of gB, downstream from the three alanine 308 mutations. In the postfusion structure of gB, V705 enters the core of domain I, the 309 domain that includes the fusion loops and interacts with the host cell membrane (Fig.  310   3B) . Mutation of V705 may influence the conformation of domain I or the refolding of 311 gB3A into a postfusion conformation. 312
Like the quadruple mutant revertant virus, the gB3A-T509M/N709H revertant 313 virus also retained the original three alanine mutations and acquired additional 314 mutations that restored fusion function. Unlike the previous revertant, both T509M and 315 N709H were required to restore gB3A function and neither mutation was 316 hyperfusogenic in WT gB background. Remarkably, N709 is located near V705 in the 317 postfusion structure (Fig. 4B) , in the portion of domain V that penetrates domain I. The 318 location of this mutation supports the importance of this region for gB fusion function. 319
Similar to V705I, N709H enhanced gB3A expression specifically, suggesting a specific 320 effect of this region on the gB3A structure. 321 T509 is a contact residue for F683 and is located in the central trimeric coiled-coil 322 of postfusion gB (Fig. 4B) . Although T509M did not restore gB3A fusion on its own, the 323 substitution of a larger hydrophobic side chain at this position may partially restore an 324 interaction between the gB arm and coil. Strikingly, in the prefusion gB model, T509 lies 325 in at the intersection of domains II, III, and IV (Fig. 4C) , near the location of S383 and 326 G645 (Fig. 3C ). Thus, mutations in this region were selected independently in two 327 revertant viruses, suggesting that the interdomain interactions at this site may impact gB 328 refolding during fusion. 329
We hypothesized that an interaction between the arm and coil regions of gB is 330 important for gB refolding and we demonstrated that fusion is impeded by gB3A 331 mutations that were designed to disrupt that interaction. Using in vitro evolution to select 332 revertant viruses, we identified two gB regions that influence gB3A, including the C-333 terminal region of domain V in postfusion gB (residues I705 and N709) and the 334 intersection of domains II, III, and IV in prefusion gB (residues S383, G645, and T509). 335
Mutations at these residues may compensate for the gB3A fusion defect by 336 destabilizing gB3A to reduce a kinetic barrier to fusion and/or enhancing gB expression. 337
To investigate how other viral proteins regulate and/or trigger gB fusion activity, future 338 work will select for revertant mutations outside of gB by passaging gB3A virus in cells 339 that express gB3A as a cellular protein. For this study, all gB mutants were cloned into the pFLAG-myc-CMV-21 359 expression vector (E5776; Sigma), substituting the gB signal sequence and adding an 360 N-terminal FLAG epitope. A FLAG-tagged gB3A construct with gB3A mutations 361 (I671A/H681A/F683A; pQF302) was subcloned from pSG5-HSVgB-362 I671A/H681A/F683A (17). Three revertant gB constructs were generated by amplifying 363 the gB gene from viral DNA isolated using a DNeasy Blood and Tissue Kit (Qiagen, 364 USA), including I671A/H681A/F683V (pQF338), 365 I671A/H681A/F683A/S383F/G645R/V701I/A855V (pQF343), and 366 I671A/H681A/F683A/T509M/N709H (pQF339). Quikchange site-directed mutagenesis 367 (ThermoFisher Scientific, USA) was used to introduce specific mutations into FLAG-368 tagged gB3A (pQF302), including S383F (pQF319), G645R (pQF320), V705I (pQF321), 369 A855V (pQF322), S383F/V705I (pQF328), G645R/V705I (pQF327), S383F/A855V 370 (pQF324), V705I/A855V (pQF325). The mutant constructs G645R/V701I/A855V 371 (pQF309), S383F/V705I/A855V (pQF310), S383F/G645R/A855V (pQF311), and 372 S383F/G645R/V705I (pQF312) were created by using Quikchange on pQF343. 373
Quikchange also was used to introduce mutations into FLAG-tagged WT gB (pQF112), 374
including S383F (pQF305), G645R (pQF306), V705I (pQF307) , A855V (pQF309), week for the WT BAC and three weeks for the gB3A BAC samples, based on when the 383 majority of cells showed RFP expression. The harvested stocks were passaged once on 384
Vero cells in roller bottles to generate virus stocks, including a WT stock and three 385 independent gB3A stocks designated 58621, 57621, and 58632. For 58632, the virus 386 stock was purified using three rounds of plaque purification using limiting dilution in 96 387 well plates. Effector and target cells were mixed in a 1:1 ratio and re-plated in 96-well plates for 18 417 h. Luciferase activity was quantified using a luciferase reporter assay system (Promega) 418 and a Wallac-Victor luminometer (Perkin Elmer). 419
Cell-based ELISA (CELISA). To evaluate the cell surface expression of gB 420 mutants, CHO-K1 cells seeded in 96-well plates were transfected with 60 ng of empty 421 vector or a gB construct using 0.15 µl of Lipofectamine 2000 (Invitrogen) diluted in Opti-422 MEM (Invitrogen). After 24 h, the cells were rinsed with phosphate buffered saline 423 (PBS) and CELISA staining was performed as previously described (31), using the 424 primary anti-FLAG MAb F1804. After incubation with primary antibody, the cells were 425 washed, fixed, and incubated with biotinylated goat anti-mouse IgG (Sigma), followed 426 by streptavidin-HRP (GE Healthcare) and HRP substrate (BioFX). 427 20 428
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